Shots:
- Innovent to receive milestones for development and commercialization along with royalties on net sales of the therapy in the licensed territory. Etana is committed to launch Byvasda in Indonesia
- The collaboration will enable Byvsada to penetrate into a Southeast Asian market and allow Innovent to bolster its presence globally
- In Jan’2020, Innovent signed an out-license agreement with Coherus to commercialize the biosimilar in the US & Canada
Click here to read full press release/ article | Ref: PRNewswire | Image: Innovent Bio
The post Innovent Out Licenses Byvasda’s (biosimilar, bevacizumab) Development and Commercialization Rights to PT Etana in Indonesia first appeared on PharmaShots.